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Abstract 
Currently, much of early phase HIV cure research involves unknown and potentially serious 
risks, with little or no chance of direct health benefits. During informed consent, 
researchers emphasize this lack of personal medical benefit to minimize misconceptions 
that undermine genuine consent. We explored participants’ and researchers’ perspectives 
on HIV cure clinical research participation and its potential benefits.  
 
We conducted semi-structured interviews with 17 HIV cure research participants and nine 
researchers in North Carolina, USA. We analyzed interviews to identify participant 
experience-related themes. We were particularly interested in indirect benefits, such as 
psychological support or improved care. We also assessed five consent documents for 
benefit/risk-related language. 
 
Research participants were male, with a median age of 50 (range: 28-62); most were non-
Hispanic white (15/17) and men who have sex with men (13/17). All 17 trial participants 
found research participation meaningful and beneficial. Reported benefits included 
improved healthcare (16/17), HIV knowledge (13/17), intimate relationships (10/17), and 
positive behaviors (6/17). Additionally, all participants described psychological benefits, 
including increased positive outlook, improved sense of purpose, emotional support, and 
enriched self-image. Participants reported risks such as quality of life concerns, 
uncomfortable procedures (e.g., leukapheresis), latency reversal, and HIV status 
disclosure. While the consent documents included discussion of these and other risks, they 
did not mention potential indirect benefits.  
 
Individuals involved in HIV clinical research have recognized participant psychological, 
social, and behavioral benefits. We recommend that researchers and institutional review 
boards consider these benefits for inclusion during risk/benefit assessments, consent 
procedures, and other discussions with prospective participants. 
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Introduction 
HIV research towards a cure has gained momentum,1 but participating in these trials 
currently offers little or no chance of direct medical benefit.2,3 Recent literature suggests 
that media announcements about cure breakthroughs4 and use of the term ‘cure’ in 
descriptions of these studies3,5-8 may increase the potential for therapeutic 
misconception9-14 among participants. That is, if HIV cure participants wrongly expect to 
receive direct medical benefits, or even cure,7,8 they may accept risks that they would not 
have otherwise.11 Emphasis on the lack of known medical benefit within consent 
documents is intended to mitigate therapeutic misconception and assist participant 
understanding of the fundamental goal of this line of research: to gain scientific knowledge 
needed to develop a future cure.15 However, this approach may also obscure important, 
indirect benefits that participants may experience and value. 
 
These indirect benefits, also referred to as inclusion16 or collateral benefits,17 are often 
received through clinical trial participation, regardless of whether or not a direct medical 
benefit is realized. Examples include access to testing, improved medical care, feelings of 
altruistic satisfaction,12,17-19 a sense of health-related agency, personal interest in the 
study, and support from research staff.20 For example, an HIV prevention trial that 
involved people who inject drugs found multiple positive social impacts among 
participants, including improvements to their lives and health, and valued gains in 
knowledge.21 
 
Qualitative research may provide a window into the potential social, behavioral, and 
psychological dimensions of clinical trial participants’ experiences, and in turn may inform 
efforts to improve the ethical conduct of research.22 This is especially important if 
researchers are unaware of or not attentive to indirect benefits. We used in-depth 
interviews with HIV cure research participants and researchers to examine participants’ 
experiences of benefits and risks, and perceptions among researchers regarding 
participants’ experiences of benefits/risks related to this research. 
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Materials and methods 
Recruitment for this study took place from February 2015 through August 2016. During 
this period, research coordinators at the University of North Carolina at Chapel Hill 
identified 28 eligible participants among volunteers for HIV cure clinical research studies. 
Research coordinators did not impose any exclusion criteria on HIV cure study participants, 
yet due to clinic/scheduling practicalities, not all 28 participants were recruited. Nineteen 
HIV cure research participants 18 years or older were recruited by clinical research 
coordinators to take part in one semi-structured, hour-long interview. Out of this 
convenience sample of 19 participants, 17 agreed to the interview.  
 
Research participants were adults living with HIV who had enrolled in HIV cure research 
involving a study intervention. These four studies included a phase I study of HIV-1 antigen 
expanded specific T-Cell therapy (HXTC),23 three phases of a histone deacetylase inhibitor 
(Vorinostat) HIV-latency reversal study,24 a Phase I/II Study to Evaluate the Kinetics of the 
Immunologic Response and Virologic Impact of AGS-004,25 and a study of the safety and 
activity of an Anti-PD-L1 antibody.26 Additionally, one participant donated cells (via 
leukapheresis) for a fifth study for use in laboratory studies related to HIV cure research.27 
Some participants took part in more than one of these clinical trials. 
 
Nine researchers were interviewed, including three research scientists, five clinical 
research support staff, and one physician-researcher whose clinic patients participated in 
cure research. Additionally, we reviewed five consent documents associated with the 
aforementioned cure studies and analyzed their contents for language related to 
discussion of potential benefits and risks. 
 
Interviews 
Interviews were conducted by one team member (AG) and recorded with each participant 
in a private office located apart from the building used to conduct the clinical trials. The 
interview guide included questions related to living with HIV, thoughts about HIV cure, and 
experiences of HIV cure research participation (e.g., researcher-participant interactions, 
benefits, risks, motivations, and effects on personal relationships). Informed consent was 
Page 5 of 22 
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obtained before interviews or recording began. A 30 USD gift card was offered to each 
interviewee (participants and researchers). All research activities received ethical approval 
from the Institutional Review Board at the University of North Carolina at Chapel Hill.  
 
Data analysis 
Audio-recorded interviews were transcribed and personal identifiers removed by one team 
member and checked for accuracy by a second. Utilizing the Framework Analysis 
approach,28 a codebook was created to define and illustrate benefit and risk-related 
themes identified within the interview guide questions, and through early analysis of 
interviewee responses. 
 
The second team member used MAXQDA 1229 to code the interview transcripts and 
informed consent documents. These codes were then reviewed for fidelity to the 
codebook by a third member. Coding inconsistencies were resolved through discussion, 
and illustrative quotes, including participant identification numbers, were identified in 
order to present typical responses within each theme. 
 
Results 
HIV cure trial participants 
The 17 HIV cure clinical research participants were all men with a median age of 50, 
ranging between 28 and 62 years. Fifteen interviewees self-identified as White, one as 
Black, and one as Latino. Fifteen reported some college education or a professional 
qualification. Thirteen identified as men who have sex with men, three identified as 
heterosexual, and one chose not to disclose his sexual identity.  
 
Participant perceptions of indirect HIV cure research benefits  
All 17 interviewees reported personal benefits related to participation in cure research 
trials. Analysis of the interviews revealed six primary benefit domains. These were: (1) 
psychological benefits, (2) indirect healthcare benefits, (3) improved understanding of HIV, 
(4) intimate relationship benefits, (5) positive behavioral changes, and (6) financial 
benefits.  
Page 6 of 22 
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Psychological benefits 
All 17 participants mentioned psychological benefits. These included increased positive 
outlook on life, improved sense of purpose, emotional support provided by research team 
members, hope, improved self-image, and useful self-reflection. Exemplary statements of 
these psychological benefits are provided in Table 1. 
 
Indirect healthcare benefits 
Sixteen of the 17 participants made statements describing the quality of healthcare during 
research. Characteristics of improved care included high quality of care providers (10/16), 
better health professional access (3/16), more HIV-related testing (offering peace of mind; 
e.g., viral load, CD4 count; 2/16), and care for other medical concerns (1/16). As one 
person explained, ‘…they do bloodwork and I know what’s going on…’ [Participant 07]. 
Another offered: ‘…there’s compassion, there’s sincerity, there’s great follow-up; [….] 
they’re honest and their integrity is top notch…’ [Participant 17]. Yet another stated, 
‘...yes, the standard of care... it’s better than if I wasn’t in the studies... I think I get a step 
up, I think there’s a step up when you’re doing this research; I just think you’ve got a heads 
up on other people’ [Participant 16]. 
 
Improved understanding of HIV 
Thirteen participants mentioned newly gained or improved understanding of HIV, or the 
state of HIV treatment or cure research specifically, as benefits of participation. One told 
us: ‘I’ve gained a lot of knowledge just from being involved in the studies and getting to 
talk to the researchers’ [Participant 03]. Increased knowledge was also linked to hope, as 
illustrated in this statement: ‘…just knowing that there are people behind the scenes 
…trying out new things and exploring different avenues and ideas. And you know, just 
trying to fight the battle and kind of keep hope alive…’ [Participant 04]. 
 
Intimate relationship benefits 
Potential benefits to intimate relationships were cited by ten participants. For an 
interviewee, who was in a long-term relationship with another participant, this benefit was 
especially poignant: ‘If anything, I feel like it’s brought us closer together. Being able to 
Page 7 of 22 
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participate…in the same studies and you know, both being in the same situation, and 
we’ve both been able to kind of help each other out in coming to study visits…’ [Participant 
03]. Another participant who did not have a partner in research, offered a similar 
sentiment: ‘I think it’s definitely brought a relative closeness, a different level …a general 
understanding for… what somebody else is going through. An emotional connection…’ 
[Participant 15].  
 
Positive behavioral changes 
Six participants described positive behavioral changes related to being in the research. 
Four of these participants cited improvements in diet and/or exercise habits; two 
mentioned safer sexual practices; and two cited a reduction in tobacco, alcohol, or drug 
use. As one explained: ‘I don’t want there to be a question asked as to whether, well, is the 
drug [Vorinostat] not working because th[is] guy’s not eating right, not exercising, not 
doing the right things. So I made it a goal to eliminate everything… [as] far as a processed 
food’ [Participant 05]. 
 
Financial benefits 
Money provided to compensate participants for time/travel across the four HIV cure 
clinical studies averaged 25 USD per hour. The length and total number of research visits 
varied by study (between one and ten hours, and five and 32 visits). However, only three 
of our participant-interviewees seemed to see this money as a notable benefit. When 
asked if he benefitted personally from taking part in research, one explained: ‘…just 
believing that I’m doing the right thing is emotionally good for me. And they do provide 
money …to compensate for these visits, but the emotional part of it is much greater… if 
they didn’t offer any money at all, I’d still come…’ [Participant 05]. 
 
Benefits in proximity to cure 
Four of the 17 trial participants made statements with a tenor that suggested their 
participation included the potential for cure, but not outright cure as a benefit. For 
instance, one said: ‘I’d be lying if I didn’t say that …I’m closer than somebody else [who is] 
sitting on their hands just taking their antiretrovirals and getting their blood checked every 
Page 8 of 22 
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three months, right. I’m closer to a cure if I’m involved in the research…’ [Participant 06]. 
Another interviewee, following a statement that referenced his own potential for cure, 
elaborated: ‘I would say the elements of me being cured are inside my body right now. [….] 
I do believe what they’ve done, has at least stepped it up to the point of, if not cured, then 
probably pretty close to that point of saying… we’ve brought this research this much 
further and now we can take it a little bit more’ [Participant 17]. Nevertheless, most 
participants seemed to have a realistic understanding and tended to focus on 
contributions to science. For instance, one told us: ‘…hopefully, something I provide may 
lead to a cure or some type of breakthrough that is able to at least begin to forward the 
research and cure process’ [Participant 15]. When asked what he might say to someone 
thinking about joining a similar study, another said: ‘…are you going to be part of a cure or 
something? Not really. This is investigational research on a variety of different things. I’d 
honestly say, “if… you see some value in [the] benefit to society, do it”’ [Participant 06]. 
 
How participants described benefits as motivating factors 
Sixteen interviews with participants suggested how perceived benefits served as 
motivators for participation in HIV cure research. The most commonly cited reason was 
altruism (13/16). For instance, when asked about the reasons why they wanted to take 
part in research, interviewees responded with the following statements: ‘I feel like I’m 
contributing to a global effort to do something really good for everyone’ [Participant 02] 
and ‘…it makes me feel better as a person …that I’m trying to help’ [Participant 07]. 
Besides altruism, participants cited hope for a cure (6/16) and financial incentives (4/16). 
In terms of hope for a cure, it was not always clear whether interviewees meant for 
themselves or for future generations, but most statements suggested hope for both. They 
also clarified that trust and relationships with researchers affected their participation 
decisions and motivations. Speaking about his involvement in what he understood to be a 
‘shock and kill’ strategy study (HIV latency reversal paired with interventions that aim to 
eliminate the virus from the body),30 one explained: ‘I’ve already agreed to doing another 
study, cause if I’m in the kill part, and [cure researcher] wants to do the shock, and it 
involved the Vorinostat, you know, I’ll trust his judgment to do that’ [Participant 17]. 
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Some participants described changing motivations over time as they learned more about 
the research, as for example: ‘…when I first heard “cure study”, my first thought is like: “I 
could be cured of this? What?” That would be awesome. But then… once I learned more 
about it, and really started thinking about it …I saw it as an opportunity to make some 
money and possibly help me cope with having the condition’ [Participant 02]. Similarly, 
another told us: ‘…initially I was thinking [that] I want to beat this. [….] But after a while, it 
became: “hey I just want to further what research is out there and see if I can maybe 
contribute in any way, shape, or form”’ [Participant 15]. 
 
Risks and barriers 
Sixteen participants talked about potential risks of being in the trial. Potential negative 
impacts on their day-to-day quality of life were the most common concerns (13/16), while 
a smaller number mentioned cancer-related risks (5/16), drug side effects (4/15), and 
disclosure of HIV status during research clinic attendance (3/16). Interestingly, one 
participant worried about the potential for participants to accept greater risks for money. 
 
Barriers to research participation were described by most of the participants (15/17). Time 
commitments (9/15) and transportation issues were most commonly mentioned (8/15). 
Two participants recognized instability or other social factors in participants’ lives as an 
important potential barrier as well. 
 
Negative experiences 
Most trial participants cited few or no negative experiences associated with HIV cure 
research. However, six did recall uncomfortable and/or painful experiences associated 
with study-related leukapheresis procedures. One participant described the need to lie to 
friends and family regarding his reasons for travel for study visits, since he preferred that 
they not know about his participation. Another participant mentioned experiencing some 
degree of conflict with an intimate partner regarding participation decisions. Still another 
expressed concerns about latency reversal. In a statement that revealed both his 
understanding of the study as well as his concern about perceived risks to others, this 
participant explained: ‘…knowing that… it amps up the viral load in my body potentially, … 
Page 10 of 22 
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it’s a little bit scarier [….] [It] feels a little weird with this study, knowing that it’s trying to 
push it [HIV] out of hiding and into my blood stream…’ [Participant 10]. 
 
Researchers’ perceptions of participant experiences 
As noted above, we interviewed nine research investigators and study staff members. 
Researcher interviews echoed participants’ statements regarding psychological benefits 
from HIV cure research. They described these benefits in terms of emotional support 
provided by research staff, sense of purpose, hope, and improved self-image. Most also 
mentioned improved medical care for participants, including personal relationships with 
staff, increased access to care providers, testing access, and increased quality of care. 
Researchers saw participants as altruistic and as dealing with their personal HIV issues 
through giving to this new area of science. For instance, one HIV physician-researcher 
explained: ‘I think there just has to be this other motivating factor, which is being part of 
something bigger than them, that this is how they can give back to their community… 
people feel like they're really doing something for science’ [Researcher 01]. Additionally, 
research staff acknowledged the risks of the experimental interventions and the potential 
for future issues that may develop from participating in these studies, such as infertility or 
cancer. 
 
Informed consent document benefit statements 
We reviewed five informed consent documents associated with the HIV cure studies that 
participants reported joining. All of the consent documents included a short section on 
potential benefits for study participants. One stated that participants would not receive 
any direct benefit; three stated that direct benefit may not exist for participants. None 
mentioned individual psychological or social benefits. All indicated that potential benefits 
would be for science, future research/patients, and/or society. One mentioned the indirect 
benefit of improved health care due to close monitoring while on study. Although our 
focus was on benefit statements, we examined the risks listed in the consent forms, which 
detailed potential risks of harm associated with the experimental intervention (e.g., side 
effects, cancer, and fertility issues), and research activities such as leukapheresis. Other 
possible risks were listed, including an inadvertent HIV status disclosure. 
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Discussion 
Few previous studies22,31 have focused on the experiences of individuals taking part in HIV 
cure research. This study expands the limited knowledge base on participants’ perceptions 
about HIV cure research3,32-35 and adds to research36 on HIV cure researchers’ perspectives 
on participant benefit. Consistent with the broader literature on indirect benefits,17-21,37,38 
and one study of four HIV cure research participants,31 our study revealed that participants 
perceive substantial benefits associated with HIV cure research, despite clear 
understanding that the research offered them has no direct medical benefit. Few of our 
interviewees mentioned risks or negative experiences related to the research, even when 
strongly encouraged to do so by the interviewer. Rather, they focused upon perceptions 
and experiences of the various benefits they received as HIV cure clinical trial participants.  
 
The 17 participants reported that taking part in these studies had a profound impact on 
their lives. All described psychological benefits, including increased positive outlook on life, 
as well as improved sense of purpose, emotional support, hope, and enriched self-image. 
Other reported benefits included improved healthcare, HIV knowledge, intimate 
relationship benefits, and positive changes in health-related behaviors. While the 
researcher-respondents reported knowledge of indirect benefits associated with research 
participation, individually they seemed less aware of the full range of potential benefits 
their participants reported experiencing.  
 
None of the informed consent documents we analyzed mentioned the potential for direct 
medical benefits. This finding is consistent with a previous analysis of HIV cure research 
consent forms, for varying types of research designs, which found that direct medical 
benefits tended to be framed as future goals, and immediate benefits framed only in 
terms of scientific progress or value to society.39 Despite this, and researchers’ best efforts 
to ensure participants understood that there were no direct medical benefits related to 
participation in HIV cure research, statements by three trial participants raised concerns 
about possible misunderstanding. Of these, two thought that they were ‘closer’ to a cure 
than non-participants, or that their participation would move them to the front of the 
queue once a cure is discovered. Ironically, a history of participation might actually make 
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them ineligible for inclusion in future HIV cure studies5 – information not mentioned in any 
of the informed consent documents we analyzed, although noted in others.39 
Nevertheless, the majority of our participants had realistic expectations and reflections on 
the potential for benefit from continued participation in HIV cure research. Hope for future 
benefits, described in the literature as therapeutic optimism, should not be equated with 
misunderstanding or therapeutic misconception.10  
 
Concerns about undue or inappropriate inducements to enroll in early phase HIV cure 
clinical trials that offer little or no direct medical benefit may lead researchers and 
Institutional Review Boards (IRBs) to omit most indirect benefits from consent forms and 
discussions. Given the perceived importance of non-medical indirect benefits associated 
with the HIV cure research studies reported in this paper, we wonder whether researchers 
should consider such benefits in risk/benefit evaluations, and indeed in informed consent 
discussions. This argument is supported by the Belmont Report40 – an established set of 
ethical principles for human subjects research that encourages taking more than just 
medical benefits into account – as well as increasing discussion in the ethics literature 
about the importance of indirect or inclusion benefits.38,41-43  
 
Our data suggest that psychological, social, behavioral, and healthcare-related benefits are 
commonly reported and valued by the HIV-cure research participants at the University of 
North Carolina at Chapel Hill. Supportive, trusting relationships with study staff or access 
to healthcare may be just as important to participants as the altruistic motivations that 
they also mention. If these benefits are found to feature commonly among participants in 
other HIV cure clinical studies around the world, then failure to mention them during 
consent may frame participation as all risk with no gain. Some have suggested that 
portraying the balance of uncertain and possibly significant risks against no direct benefit 
in HIV cure trials makes participation a ‘bad deal’.44 This striking contrast between the 
risk/benefit relationship as seen by third parties and by research participants is at least 
worth exploring. If these benefits are real, what justifies them being inadmissible from an 
ethical point of view? We suggest that appropriately forecasting the potential for indirect 
benefits may facilitate more accurate risk/benefit calculations for potential participants. 
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The fact that researchers cannot guarantee that some or all of these benefits will be 
experienced by every participant does not, we argue, justify ignoring them. 
 
In short, one might argue that the reasons in favor of mentioning such benefits (at least as 
possibilities) during the consent process and of making them part of ethical assessments of 
risks and benefits are stronger than the reasons to exclude them. However, even if radical 
exclusion of such benefits is hard to justify, inclusion of such benefits in the consent 
process remains ethically challenging. There is tension between denying the reality of 
indirect benefits on the one hand, and creating added risks by communicating them to 
prospective participants on the other. As our study suggests, many participants are 
motivated by altruism, and mention of these benefits might crowd out some positive 
motivations, by directing participants’ focus toward their potential for personal gain. In 
certain contexts, such as low-resource settings, telling prospective participants about 
potential indirect benefits might lead to ‘undue inducement’ – that is, disproportionate 
prospects of benefit that may inappropriately lead participants to discount risks.45 
Therefore, there exists a possibility that mentioning indirect benefits during informed 
consent could reduce the quality of consent, if decisions to participate are based on 
expectations of indirect benefit that never materialize for a given participant. In addition, 
since informed consent does not involve disclosing all possible information related to a 
study, the inclusion of indirect benefits needs to be justified, presumably on a contextual, 
selective, study-by-study basis, informed by prior experiences observed in methodically 
similar studies. Guidelines should be developed to help determine whether and how to 
take indirect benefits into account in ethical review, research communications, and study 
documents. While this may be a real concern, since indirect risks are infrequently 
mentioned in research practice, it is difficult to know. These are important and neglected 
issues, and should be the focus of future empirical and conceptual research. 
 
Limitations 
Our research has at least three major limitations. First, this was a small, qualitative study 
of participants and researchers at one research site. The majority of the cure study 
participants were White and male with a median age of 50, thus lacking diversity and 
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limiting the generalizability of our findings. Lack of success in recruiting women for 
interviews, despite focused efforts by the study team, is especially unfortunate.46 Second, 
few interviewees recalled any negative experiences. This suggests a possible selection bias 
for participants with overall positive research experiences, since those with negative 
experiences might have declined the interviews. Alternatively, interviewees could have 
emphasized positive experiences in attempts to please researchers. This research was 
conducted at the researchers’ own university. While interviews were conducted outside 
the context of the clinical trials, and the interviewer was not associated with the clinical 
studies, interviewees nevertheless may have been reluctant to report negative 
experiences associated with clinical research participation. An additional factor might be 
retrospective bias: interviewees might be uncomfortable recalling or mentioning negative 
experiences, since doing so might call into question their own motivations or original 
decisions to participate in the research. Although we tried to build rapport, make 
respondents comfortable, and reassure them about the confidentiality of the interviews, 
these potential biases cannot be ruled out. Additionally, it could be that perceptions of 
trial benefits were heightened due to the novelty and potential specialness of research 
efforts to cure HIV. While the similarities in benefit perception between study participants 
and investigators suggest that participants were not subject to misunderstandings or social 
desirability bias, future research should be designed to confirm this finding in a 
quantifiable way. Third, descriptions provided by participants may reflect total research 
experiences, including other, previous non-HIV cure studies. For instance, for 
approximately half of our respondents, study-related emotional support for living with HIV 
emerged from participating in previous treatment trials rather than the HIV cure trials that 
were the subject of our study. For serial trial participants, the impact of cumulative 
research experience is unsurprising, but sometimes challenging to parse.  
 
Conclusion 
Analyses of informed consent,39,47,48 participant motivations,3,49 and understandings of 
risks versus benefits2,37,50,51 are essential to improving the ethical conduct of HIV cure 
research.22 Through a qualitative analysis of participant interviews, we identified 
substantial unanticipated benefits associated with HIV cure research. While this study was 
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exploratory, our data show that indirect benefits are important to HIV cure clinical 
research participants and may contribute to their motivations to take part in future 
studies. Additionally, our data reveal how participants’ perceptions of benefits and 
motivations may change over time. For instance, while the initial excitement of taking part 
in HIV cure research seems to fade with time, it may be replaced by a genuine sense of 
‘doing good’ and of taking part in something greater and more important than oneself.   
 
Given the limitations of this small qualitative study, much more research is needed from 
multiple sites, including larger, more diverse, cross-cultural, representative samples. This 
further work will be necessary in order to determine how these benefits might affect 
participant enrolment and retention, especially across multiple and/or serial studies. 
Moreover, future research should address participants’ decision-making processes over 
time,3 especially their assessments of risks vs. benefits,2,37,50,51 when given the opportunity 
to join a cure trial.  
 
While not generalizable, our data suggest at the very least that some participants in HIV 
cure clinical trials experience indirect psychological, social, and behavioral benefits that 
they find to be meaningful and valuable within the context of studies in which they are 
instructed not to expect benefits. Certainly, experiences of non-medical inclusion benefits 
are subjective, often contingent on factors beyond researchers’ control, and would need 
to be communicated with care; however, coupled with continued ethical evaluation, our 
study suggests that researchers might contemplate discussing these benefits with 
potential participants during informed consent. Additionally, IRBs may encourage 
consideration of these often-unacknowledged benefits during risk/benefit evaluations. We 
suggest that researchers and IRBs address their possibility, and be encouraged to develop 
appropriate ways to describe such benefits.  
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Table 1. HIV cure study participant quotes depicting psychological benefits of HIV cure 
research in North Carolina, 2015-2016 (N= 17).  
Ps
yc
ho
lo
gi
ca
l b
en
ef
its
 
Positive 
outlook 
(11/17)* 
‘So as I participate, I tend to learn more and soak things in and that 
helps me put a positive spin on what initially was very, very negative.’ 
[Participant 01]  
Sense of 
purpose 
(10/17) 
‘I just feel that by participating I’m extending my life. I feel that by 
participating I’m working toward a goal, working toward finding a 
cure, helping the researchers.’ [Participant 16]  
Emotional 
support 
(staff) 
(10/17) 
‘It’s definitely made the experience a lot easier: people that seem to 
understand and want to help; and then put you at ease, to come up 
here just to help any apprehension that somebody might have.’ 
[Participant 15]  
Hope 
(6/17) 
‘I have hope again; honestly, I really do have hope again. [….] … I want 
to be around for a very long time, I have a lot more to accomplish; it’s 
given me hope that, you know, I’m doing something proactive….’ 
[Participant 17]  
Improved 
self-image 
(6/17) 
‘Being part of the study both feeling like I’m contributing to something 
good and learning more of the science behind it has helped me view 
myself in a much, much better light.’ [Participant 02]  
Useful 
self-
reflection 
(4/17) 
‘[Participation] has kind of changed the way I see myself as someone 
living with HIV, but still doing what I can to help prevent more people 
from becoming infected and sick from HIV.’ [Participant 03] 
* The number of participants citing the benefit is in parentheses. 
